HIV Vaccine Research and Development
Sector: Manufacturing (Industrial) • Location: Brooklyn, Manhattan, City of New York
Source: World Bank Group
The development objective of this project is to develop and characterize viable HIV vaccine candidate(s) and other potential viral vectors as basic research for new technologies against infectious diseases of poverty. The project has two components. The first component, research and development (R&D), will support activities to develop an HIV vaccine candidate, including vector optimization and de
- Status
- Closed
- Sector
- Manufacturing (Industrial), Government
- Location
- United States of America
- Updated
- 22 Jul 2026
- Source
- World Bank Group
ConstructChat
Ask ConstructChat about HIV Vaccine Research and Development
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | closed |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | The development objective of this project is to develop and characterize viable HIV vaccine candidate(s) and other potential viral vectors as basic research for new technologies against infectious diseases of poverty. The project has two components. The first component, research and development (R&D), will support activities to develop an HIV vaccine candidate, including vector optimization and development of a related viral presentation platform. This will entail further research on the transcriptomic and immunological response to the VSV-vectored HIV vaccine candidates and applied research to address optimization of methods related to effective vaccine production. The component will also include activities to establish a VSV vector platform for development of vaccines against variety of infectious diseases. The pillars of this component are detailed immunologic and transcriptomics analysis on samples collected from studies funded by IAVI and other collaborating partners; and applied research aimed at developing a cell line that will support GMP-manufacturing of Gpseudotyped VSVΔG-Env. The second component, knowledge dissemination and coordination (non-R&D) component, will strengthen coordination among key global stakeholders to promote further engagements of the global scientific community, private sector and other stakeholders. The pillars of this component are regular scientific stakeholder meeting co-organized by key global stakeholders; development of communication material; and field visits to IAVI Clinical Research Centers. |
Original sector | FY17 - Health |
Budget |
Location
Country | United States of America (USA) |
Source
Source | World Bank Group |
URL |
More Details
Record type | Project |
Sector | Manufacturing (Industrial), Government |
Article published date | 2025-12-17 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
